期刊
VACCINE
卷 29, 期 16, 页码 3074-3082出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2011.01.075
关键词
Viral vector; Bovine herpesvirus 4; BTV; VP2
资金
- Italian Ministry of University and Scientific Research (Italian National Grant MIUR)
- Fondazione Cariparma (Cassa di Risparmio di Parma, Italy)
- Comision Interministerial de Ciencia y Tecnologia (CICYT) [AGL2008-00646/GAN]
- EU Network of Excellence EPIZONE [FOOD-CT-2006-016236]
New effective tools for vaccine strategies are necessary to limit the spread of bluetongue, an insect-transmitted viral disease of domestic and wild ruminants. In the present study. BoHV-4-based vector cloned as a bacterial artificial chromosome (BAC) was engineered to express the bluetongue virus (BTV) immune-dominant glycoprotein VP2 provided of a heterologous signal peptide to its amino terminal and a trans-membrane domain to its carboxyl terminal (IgK-VP2gDtm), to allow the VP2 expression targeting to the cell membrane fraction. Based on adult alpha/beta interferon receptor knockout (IFNAR((-/-))) mice, a newly generated bluetongue laboratory animal model, a pre-challenge experiment was performed to test BoHV-4 safety on such immune-compromised animal. BoHV-4 infected IFNAR((-/-)) mice did not show clinical signs even following the inoculation of BoHV-4 intra-cerebrally, although many areas of the brain got transduced. IFNAR((-/-)) mice intraperitoneally inoculated twice with BoHV-4-A-IgK-VP2gDtm at different time points developed serum neutralizing antibodies against BTV and showed a strongly reduced viremia and a longer survival time when challenged with a lethal dose of BTV-8. The data acquired in this pilot study validate BoHV-4-based vector as a safe and effective heterologous antigen carrier/producer for the formulation of enhanced recombinant immunogens for the vaccination against lethal bluetongue. (C) 2011 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据